• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌的治疗策略:扩大射频消融的适应证

Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation.

作者信息

Tateishi Ryosuke, Shiina Shuichiro, Ohki Takamasa, Sato Takahisa, Masuzaki Ryota, Imamura Jun, Goto Eriko, Goto Tadashi, Yoshida Hideo, Obi Shuntaro, Sato Shinpei, Kanai Fumihiko, Yoshida Haruhiko, Omata Masao

机构信息

Department of Gastroenterology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

出版信息

J Gastroenterol. 2009;44 Suppl 19:142-6. doi: 10.1007/s00535-008-2247-9. Epub 2009 Jan 16.

DOI:10.1007/s00535-008-2247-9
PMID:19148809
Abstract

BACKGROUND

Radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is ordinarily indicated for those with three or fewer nodules, none of which exceeds 3 cm in diameter. This study investigated whether an apparent threshold exists in the diameter and number of nodules in terms of the prognosis of patients with HCC.

METHODS

We enrolled 663 naïve patients with HCC who were treated with RFA at our hospital between 1999 and 2005. We analyzed the patients' prognosis using multivariate Cox proportional regression with the diameter and number of nodules as covariates and Child-Pugh class as a stratification factor. The diameter and number were categorized as <or=2.0, 2.1-3.0, 3.1-4.0, 4.1-5.0, and >5 cm and 1, 2-3, 4-5, and >5, respectively.

RESULTS

The adjusted hazard ratio of patients whose largest nodule was <or=2.0, 2.1-3.0, 3.1-4.0, 4.1-5.0, and >5 cm was 1, 1.51, 2.56, 2.25, and 2.71, respectively. The adjusted hazard ratio of patients with one, two or three, four or five, and more than five nodules was 1, 1.35, 1.70, and 2.12, respectively. Therefore, patients with three or fewer nodules, none of which exceeds 5 cm in diameter, have a 5-year survival of 40%.

CONCLUSIONS

The prognosis of the patients worsened gradually as the diameter and number of nodules increased. No apparent threshold in the diameter or number of HCC nodules was detected. RFA can be applied beyond the conventional indications.

摘要

背景

肝细胞癌(HCC)的射频消融(RFA)通常适用于结节数为三个或更少且直径均不超过3 cm的患者。本研究调查了HCC患者的预后在结节直径和数量方面是否存在明显的阈值。

方法

我们纳入了1999年至2005年间在我院接受RFA治疗的663例初治HCC患者。我们以结节直径和数量作为协变量,Child-Pugh分级作为分层因素,采用多因素Cox比例回归分析患者的预后。直径和数量分别分为≤2.0、2.1 - 3.0、3.1 - 4.0、4.1 - 5.0和>5 cm以及1、2 - 3、4 - 5和>5。

结果

最大结节直径≤2.0、2.1 - 3.0、3.1 - 4.0、4.1 - 5.0和>5 cm的患者调整后风险比分别为1、1.51、2.56、2.25和2.71。结节数为1、2或3、4或5以及超过5个的患者调整后风险比分别为1、1.35、1.70和2.12。因此,结节数为三个或更少且直径均不超过5 cm的患者5年生存率为40%。

结论

随着结节直径和数量的增加,患者的预后逐渐恶化。未检测到HCC结节直径或数量的明显阈值。RFA可应用于超出传统适应证的情况。

相似文献

1
Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation.肝细胞癌的治疗策略:扩大射频消融的适应证
J Gastroenterol. 2009;44 Suppl 19:142-6. doi: 10.1007/s00535-008-2247-9. Epub 2009 Jan 16.
2
Percutaneous radiofrequency ablation for early hepatocellular carcinoma: risk factors for survival.早期肝细胞癌的经皮射频消融:生存的危险因素
World J Gastroenterol. 2014 Feb 14;20(6):1585-93. doi: 10.3748/wjg.v20.i6.1585.
3
Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up.经皮射频消融作为小肝癌的一线治疗:长期随访结果和预后因素。
J Gastroenterol Hepatol. 2010 Mar;25(3):597-604. doi: 10.1111/j.1440-1746.2009.06125.x. Epub 2010 Jan 14.
4
Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.经动脉化疗栓塞术与射频消融术治疗不可切除的巴塞罗那临床肝癌分期0/A期肝细胞癌的比较:倾向评分匹配法
J Gastroenterol Hepatol. 2016 Feb;31(2):442-9. doi: 10.1111/jgh.13077.
5
Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.经动脉化疗栓塞联合射频消融治疗早期肝细胞癌。
Korean J Intern Med. 2016 Mar;31(2):242-52. doi: 10.3904/kjim.2015.112. Epub 2016 Feb 15.
6
[Long term (5 years) outcome of radiofrequency ablation for hepatocellular carcinoma in 256 cases].256例肝细胞癌患者射频消融的长期(5年)疗效
Beijing Da Xue Xue Bao Yi Xue Ban. 2005 Dec 18;37(6):671-2.
7
Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.肝细胞癌立体定向体部放射治疗或射频消融后的疗效
J Clin Oncol. 2016 Feb 10;34(5):452-9. doi: 10.1200/JCO.2015.61.4925. Epub 2015 Nov 30.
8
Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation.开发和验证用于接受射频消融治疗的肝细胞癌患者的预后模型。
Cancer Med. 2019 Sep;8(11):5023-5032. doi: 10.1002/cam4.2417. Epub 2019 Jul 10.
9
Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma.经导管动脉化疗栓塞联合或不联合射频消融治疗巴塞罗那临床肝癌分期 B 期肝细胞癌的疗效比较。
AJR Am J Roentgenol. 2018 Apr;210(4):891-898. doi: 10.2214/AJR.17.18177. Epub 2018 Feb 7.
10
Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.射频消融作为潜在可移植患者小于 3cm 的肝细胞癌一线治疗的结果。
J Hepatol. 2019 May;70(5):866-873. doi: 10.1016/j.jhep.2018.12.027. Epub 2019 Jan 5.

引用本文的文献

1
Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma.亚洲肿瘤消融治疗肝细胞癌指南会议
Liver Cancer. 2025 Mar 3:1-27. doi: 10.1159/000544976.
2
Efficacy and prognostic factors of repeated hepatectomy for postoperative intrahepatic recurrence of hepatocellular carcinoma undergoing initial hepatectomy.初次肝切除术后肝细胞癌肝内复发再次肝切除的疗效及预后因素
Front Med (Lausanne). 2023 May 11;10:1127122. doi: 10.3389/fmed.2023.1127122. eCollection 2023.
3
Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Enhances the Antitumor Efficacy of Radiofrequency Ablation.

本文引用的文献

1
Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial.经动脉化疗栓塞联合射频消融治疗直径大于3cm的肝细胞癌患者:一项随机对照试验
JAMA. 2008 Apr 9;299(14):1669-77. doi: 10.1001/jama.299.14.1669.
2
Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?微泡增强超声检查对早期肝细胞癌患者经皮治疗反应的评估是否足够?
Eur Radiol. 2006 Nov;16(11):2454-62. doi: 10.1007/s00330-006-0264-8. Epub 2006 May 18.
3
Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations.
溶瘤性疱疹病毒G47Δ的新辅助使用增强了射频消融的抗肿瘤疗效。
Mol Ther Oncolytics. 2020 Aug 21;18:535-545. doi: 10.1016/j.omto.2020.08.010. eCollection 2020 Sep 25.
4
Survival benefit of radiofrequency ablation for solitary (3-5 cm) hepatocellular carcinoma: An analysis for nationwide cancer registry.射频消融治疗孤立性(3-5厘米)肝细胞癌的生存获益:一项基于全国癌症登记处的分析
Medicine (Baltimore). 2017 Nov;96(44):e8486. doi: 10.1097/MD.0000000000008486.
5
Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRI.用于评估非手术性肝细胞癌治疗反应的成像模态:对比增强超声、CT和MRI。
Liver Cancer. 2015 Mar;4(2):106-14. doi: 10.1159/000367733. Epub 2015 Apr 8.
6
CT-guided Interstitial Brachytherapy of Hepatocellular Carcinoma before Liver Transplantation: an Equivalent Alternative to Transarterial Chemoembolization?肝移植前CT引导下肝细胞癌间质近距离放射治疗:经动脉化疗栓塞的等效替代方案?
Eur Radiol. 2015 Sep;25(9):2608-16. doi: 10.1007/s00330-015-3660-0. Epub 2015 Mar 4.
7
Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI.肝癌射频消融治疗反应评估:超声造影、CT和MRI
World J Gastroenterol. 2014 Apr 21;20(15):4160-6. doi: 10.3748/wjg.v20.i15.4160.
8
CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients: a randomized controlled trial.CT 肝动脉造影作为肝细胞癌患者预处理检查的随机对照试验。
Am J Gastroenterol. 2013 Aug;108(8):1305-13. doi: 10.1038/ajg.2013.109. Epub 2013 Apr 30.
9
Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.自身免疫性肝炎中的肝细胞癌和其他恶性肿瘤。
Dig Dis Sci. 2013 Jun;58(6):1459-76. doi: 10.1007/s10620-012-2525-5. Epub 2013 Jan 10.
10
Resection and radiofrequency ablation in the treatment of hepatocellular carcinoma: a single-center experience.切除与射频消融治疗肝细胞癌:单中心经验。
Surg Endosc. 2012 Apr;26(4):990-7. doi: 10.1007/s00464-011-1983-8. Epub 2011 Oct 25.
对所谓高危部位肝细胞癌的射频消融治疗。
Hepatology. 2006 May;43(5):1101-8. doi: 10.1002/hep.21164.
4
Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion.动脉内注射5-氟尿嘧啶与全身应用α-干扰素联合治疗伴门静脉侵犯的晚期肝细胞癌
Cancer. 2006 May 1;106(9):1990-7. doi: 10.1002/cncr.21832.
5
A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma.一项比较经皮局部消融治疗与部分肝切除术治疗小肝细胞癌的前瞻性随机试验。
Ann Surg. 2006 Mar;243(3):321-8. doi: 10.1097/01.sla.0000201480.65519.b8.
6
Radiation therapy for portal venous invasion by hepatocellular carcinoma.肝细胞癌门静脉侵犯的放射治疗
World J Gastroenterol. 2005 Dec 14;11(46):7237-41. doi: 10.3748/wjg.v11.i46.7237.
7
Management of hepatocellular carcinoma.肝细胞癌的管理
Hepatology. 2005 Nov;42(5):1208-36. doi: 10.1002/hep.20933.
8
Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study.经皮乙醇注射与手术切除治疗小肝细胞癌的前瞻性研究。
Ann Surg. 2005 Jul;242(1):36-42. doi: 10.1097/01.sla.0000167925.90380.fe.
9
Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients.肝细胞癌新预后模型的提议:对403例患者的分析
Gut. 2005 Mar;54(3):419-25. doi: 10.1136/gut.2003.035055.
10
Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.经皮射频消融治疗肝细胞癌。1000例分析。
Cancer. 2005 Mar 15;103(6):1201-9. doi: 10.1002/cncr.20892.